Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.

Conclusions: Data highlight the value of molecular profiling in identifying populations with high unmet needs with potentially favorable response characteristics and accelerating development of novel therapies for these patients. Clin Cancer Res; 1-10. ©2018 AACR. PMID: 30442684 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30442684?dopt=Abstract

Source: Clinical Cancer Research - November 15, 2018 Category: Cancer & Oncology Authors: Ayers M, Nebozhyn M, Cristescu R, McClanahan TK, Perini R, Rubin E, Cheng JD, Kaufman DR, Loboda A Tags: Clin Cancer Res Source Type: research